Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group

TEL AVIV, Israel, May 05, 2017 (GLOBE NEWSWIRE) — Alcobra Ltd. (ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that it has reached an agreement (the “Agreement”) with Brosh Capital L.P. and certain of its affiliates (the “Brosh Group”) on the cancellation of the Extraordinary General Meeting of Shareholders previously called by the Brosh Group to be held on May 23, 2017 (the “Extraordinary General Meeting”).